ALN-SOD

PreclinicalSmall molecule

Regeneron

ALN-SOD is one of 46 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

Amyotrophic Lateral Sclerosis (ALS)Recruiting

Amyotrophic Lateral SclerosisPhase 1/Phase 2

Active, not recruiting

Amyotrophic Lateral Sclerosis (ALS)Preclinical

Recruiting

Competition

Competitive Landscape

220 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

2 2

Radicava

Shionogi

Phase 3

2 3

Simdax

Orion Corporation, Orion Pharma

Phase 3

1 4

Robitussin

Ultomiris

Lithobid

SSolvay Pharmaceuticals

Phase 3

3 7

Minocin

TTriax

Phase 3

2 8

Sodium Valproate

AstraZeneca

Phase 3

1 9

BOTULINUM TOXIN TYPE B

Eisai

Phase 3

1 10

Namenda

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

PreclinicalRecruiting

Amyotrophic Lateral Sclerosis (ALS)

NCT06351592

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations

Recruiting· Regeneron logo

Regeneron·Preclinical·NCT06351592·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALN-SOD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALN-SOD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALN-SOD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Regeneron

ALN-SOD

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

References

Drug Info

Quick Facts

Related News